Predict your next investment

Venture Capital
mpmcapital.com

See what CB Insights has to offer

Investments

429

Portfolio Exits

122

Funds

16

Partners & Customers

4

Service Providers

3

About MPM Capital

MPM Capital is a Boston-based life science-dedicated venture investor with committed capital under management in excess of $2 billion. MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area.

MPM Capital Headquarter Location

450 Kendall Street

Cambridge, Massachusetts, 02142,

United States

617-425-9200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest MPM Capital News

07:30 ET CODA Biotherapeutics Closes $28 Million Financing led by Pacira BioSciences

Dec 2, 2021

Includes participation from existing investors - MPM Capital and Versant Ventures Leading non-opioid pain management company Pacira BioSciences joins as equity investor in CODA's chemogenetic gene therapy platform to treat neurological disorders News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., Dec. 2, 2021 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders with an initial focus on neuropathic pain and epilepsy, today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc., together with the company's existing investors, MPM Capital and Versant Ventures, and a new venture debt round with Silicon Valley Bank (SVB). As part of the financing, David Stack, chairman and CEO of Pacira Biosciences, has joined CODA's board of directors. "We are pleased to have Pacira BioSciences join our existing investors in supporting our mission to develop novel chemogenetic therapies for the treatment of neurological disorders for which current treatment options have significant limitations," said Michael Narachi, president and CEO of CODA. "We have significantly increased our cash balances to fuel continued progress on our platform with an initial focus on neuropathic pain and focal epilepsy. The equity investment capital from Pacira BioSciences, one of the world's leading non-opioid pain management companies, further validates our approach and will help us progress our neuropathic pain therapies toward human clinical trials where we hope to demonstrate transformative results for patients." "We are extremely excited to back the CODA team and their groundbreaking chemogenetic gene therapy platform," said Mr. Stack. "We believe the CODA approach could transform the treatment paradigm for neuropathic pain and help millions of patients." About the CODA Platform  CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach by deploying a chemogenetic strategy for treating neurological disorders. The Company's innovative treatment aims to modulate specific neuronal circuits via adeno-associated virus (AAV)-mediated delivery of an engineered, inhibitory receptor by standard-of-care neurosurgical procedures. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable results while potentially avoiding off-target/adverse effects of currently available treatments. About Neuropathic Pain and Focal Epilepsy  According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain – an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction. Epilepsy is one of the most common chronic neurological diseases and, according to the Centers for Disease Control, affects more than 65 million people around the world of which 3.4 million are in the U.S. Epilepsy is characterized by unpredictable seizures and the term "focal" epilepsy is used to describe seizures that initiate from a specific location in the brain, typically in one hemisphere. Focal epilepsy represents approximately 60 percent of all epilepsy (National Institute of Neurological Disorders and Strokes). According to the World Health Organization, recurrent seizures disrupt normal brain functions, lead to neuronal loss, and result in cognitive and emotional deficits. Patients suffer from stigmatization, social isolation, combined with disability, educational underachievement, and poor employment outcomes. The Epilepsy Foundation estimates that one-third of people with epilepsy live with uncontrollable seizures because no available treatments are effective. About CODA Biotherapeutics   CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit www.codabiotherapeutics.com . SOURCE CODA Biotherapeutics, Inc.

MPM Capital Investments

429 Investments

MPM Capital has made 429 investments. Their latest investment was in CODA Biotherapeutics as part of their Series B on December 12, 2021.

CBI Logo

MPM Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/2/2021

Series B

CODA Biotherapeutics

$28M

No

2

10/28/2021

Series A

Protego Biopharma

$51.05M

Yes

2

10/21/2021

Series B

Recode Therapeutics

$80M

No

5

7/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/2/2021

10/28/2021

10/21/2021

7/12/2021

6/15/2021

Round

Series B

Series A

Series B

Series B

Series B

Company

CODA Biotherapeutics

Protego Biopharma

Recode Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$28M

$51.05M

$80M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

5

10

10

MPM Capital Portfolio Exits

122 Portfolio Exits

MPM Capital has 122 portfolio exits. Their latest portfolio exit was Blade Therapeutics on November 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2021

Acq - Pending

$991

1

10/29/2021

IPO

$991

1

6/17/2021

Reverse Merger

$991

13

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

11/8/2021

10/29/2021

6/17/2021

00/00/0000

00/00/0000

Exit

Acq - Pending

IPO

Reverse Merger

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

13

10

10

MPM Capital Acquisitions

4 Acquisitions

MPM Capital acquired 4 companies. Their latest acquisition was Pacira Biosciences on March 05, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/5/2007

Debt

$991

$111.25M

Acq - Fin

8/15/2001

Unattributed VC

Subscribe to see more

$991

$99M

Subscribe to see more

10

6/12/2001

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/5/2007

8/15/2001

6/12/2001

Investment Stage

Debt

Unattributed VC

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$111.25M

$99M

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

10

MPM Capital Fund History

16 Fund Histories

MPM Capital has 16 funds, including MPM Oncology Impact Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/6/2021

MPM Oncology Impact Fund II

$850M

1

2/26/2020

MPM Oncology Innovations Fund

Early-Stage Venture Capital

$98.88M

5

2/21/2019

MPM BioVentures 2018

Early-Stage Venture Capital

$400M

5

7/9/2015

MPM BioVentures 2014

Subscribe to see more

$99M

10

3/24/2015

MPM Bio 2014 NVS Strategic Fund

Subscribe to see more

$99M

10

Closing Date

10/6/2021

2/26/2020

2/21/2019

7/9/2015

3/24/2015

Fund

MPM Oncology Impact Fund II

MPM Oncology Innovations Fund

MPM BioVentures 2018

MPM BioVentures 2014

MPM Bio 2014 NVS Strategic Fund

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$850M

$98.88M

$400M

$99M

$99M

Sources

1

5

5

10

10

MPM Capital Partners & Customers

4 Partners and customers

MPM Capital has 4 strategic partners and customers. MPM Capital recently partnered with DigiTx Partners, and Astellas Pharma on April 4, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

4/22/2019

Partner

DigiTx Partners, and Astellas Pharma

United States, and Japan

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital — digiTx Partners

Tokyo and San Francisco , July 29 , 2016 -- Astellas Pharma Inc. and DigiTx Partner 's LLC announce that Astellas Pharma Inc. has launched DigiTx Partners LLC , a digital health investment company in partnership with MPM Capital , Inc. .

1

7/30/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/14/2015

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/22/2019

7/30/2016

5/14/2015

Type

Partner

Partner

Partner

Partner

Business Partner

DigiTx Partners, and Astellas Pharma

Country

United States, and Japan

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital — digiTx Partners

Tokyo and San Francisco , July 29 , 2016 -- Astellas Pharma Inc. and DigiTx Partner 's LLC announce that Astellas Pharma Inc. has launched DigiTx Partners LLC , a digital health investment company in partnership with MPM Capital , Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

MPM Capital Service Providers

3 Service Providers

MPM Capital has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Subscribe to see more

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

MPM Capital Team

49 Team Members

MPM Capital has 49 team members, including current Founder, Managing Director, Luke Evnin.

Name

Work History

Title

Status

Luke Evnin

Founder, Managing Director

Current

Patrick A Baeuerle

Managing Director

Current

Chris Bardon

Managing Director

Current

Mitchell H Finer

Managing Director

Current

Todd Foley

Managing Director

Current

Name

Luke Evnin

Patrick A Baeuerle

Chris Bardon

Mitchell H Finer

Todd Foley

Work History

Title

Founder, Managing Director

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.